NHS launches Pharmacy First to treat seven common conditions
Over 10,000 pharmacies in England will be offering the new advanced service
Read Moreby Jen Brogan | Jan 31, 2024 | News | 0
Over 10,000 pharmacies in England will be offering the new advanced service
Read Moreby Jen Brogan | Aug 23, 2023 | News | 0
The varicella zoster virus that causes shingles and chicken pox is typically present in over 90% of adults globally
Read Moreby Lucy Parsons | Sep 2, 2021 | News | 0
Jab aimed at adults aged 50 years and older and those at increased risk
Read Moreby Anna Smith | May 2, 2019 | News | 0
The results showed revenue growth across all three of GSK’s divisions.
Read Moreby Selina McKee | Nov 1, 2018 | News | 0
GSK says it now expects full-year earnings at the upper end of its guidance after continued sales growth during the third quarter and the delay to generic competition for one of its key products.
Read Moreby Selina McKee | Oct 26, 2017 | News | 0
The US Centre for Disease Control Prevention’s Advisory Committee on Immunisation Practices (ACIP) has given its backing to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck & Co’s veteran vaccine Zostavax.
Read Moreby Selina McKee | Oct 23, 2017 | News | 0
GlaxoSmithKline’s Shingrix has been approved in the US for protection against shingles in adults aged 50 years or older.
Read Moreby Selina McKee | Nov 28, 2016 | News | 0
GlaxoSmithKline has submitted its experimental shingles vaccines to European regulators, seeking approval to market its use to prevent herpes zoster (shingles) in people aged 50 years or over.
Read Moreby Selina McKee | Oct 31, 2016 | News | 0
GSK has unveiled new data for its shingles candidate vaccine Shingrix from trials assessing its co-administration with the flu vaccine, dosing schedule and quality of life.
Read Moreby Selina McKee | Oct 24, 2016 | News | 0
GlaxoSmithKline has filed Biologics License Application in the US for Shingrix, seeking approval to market the vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or over.
Read Moreby Selina McKee | Jul 19, 2016 | News | 0
Sanofi Pasteur MSD’s shingles (herpes zoster) vaccine has been cleared for continued use in the UK’s national immunisation programme for at least the next two years, following an evaluation of the vaccine’s clinical and cost effectiveness.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479